News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,469 Results
Type
Article (13874)
Company Profile (295)
Press Release (246300)
Section
Business (79340)
Career Advice (150)
Deals (13195)
Drug Delivery (32)
Drug Development (50312)
Employer Resources (31)
FDA (5673)
Job Trends (5113)
News (144120)
Policy (10015)
Tag
Academia (901)
Alliances (21473)
Alzheimer's disease (736)
Approvals (5648)
Artificial intelligence (63)
Bankruptcy (97)
Best Places to Work (4498)
Biotechnology (242)
Breast cancer (66)
Cancer (699)
Cardiovascular disease (62)
Career advice (131)
CAR-T (57)
Cell therapy (179)
Clinical research (39832)
Collaboration (239)
Compensation (99)
COVID-19 (1002)
C-suite (68)
Cystic fibrosis (66)
Data (798)
Diabetes (73)
Diagnostics (1201)
Earnings (28986)
Events (46904)
Executive appointments (193)
FDA (5967)
Funding (252)
Gene editing (55)
Gene therapy (148)
GLP-1 (301)
Government (1063)
Healthcare (6534)
Infectious disease (1037)
Inflammatory bowel disease (94)
IPO (7196)
Job creations (859)
Job search strategy (126)
Layoffs (184)
Legal (1373)
Lung cancer (111)
Manufacturing (74)
Medical device (2552)
Medtech (2553)
Mergers & acquisitions (6103)
Metabolic disorders (225)
Neuroscience (946)
NextGen Class of 2024 (1998)
Non-profit (844)
Northern California (951)
Obesity (124)
Opinion (91)
Parkinson's disease (61)
Patents (52)
People (24988)
Pharmaceutical (50)
Phase I (14023)
Phase II (18525)
Phase III (11737)
Pipeline (325)
Postmarket research (846)
Preclinical (5938)
Radiopharmaceuticals (205)
Rare diseases (169)
Real estate (1409)
Regulatory (8207)
Research institute (931)
Southern California (868)
Startups (1965)
United States (7659)
Vaccines (160)
Weight loss (76)
Date
Last 7 days (419)
Last 30 days (2059)
Last 365 days (20755)
2024 (19079)
2023 (22462)
2022 (26860)
2021 (27820)
2020 (23365)
2019 (16225)
2018 (11738)
2017 (13749)
2016 (11839)
2015 (14350)
2014 (10393)
2013 (7484)
2012 (7533)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16836)
Australia (2839)
California (2158)
Canada (718)
China (166)
Colorado (82)
Connecticut (86)
Europe (36295)
Florida (232)
Georgia (62)
Illinois (126)
Indiana (54)
Kansas (55)
Maryland (300)
Massachusetts (1712)
Michigan (48)
Minnesota (94)
New Jersey (549)
New York (620)
North Carolina (399)
Northern California (951)
Ohio (79)
Pennsylvania (429)
South America (207)
Southern California (868)
Texas (232)
Washington State (221)
260,469 Results for "gammadelta therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
IN8bio, Inc. a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell platform, known as INB-300, that demonstrated improved selectivity to target leukemia cells while preserving healthy ones.
April 9, 2024
·
7 min read
Pharm Country
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
IN8bio presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene & Cell Therapy 2024 Annual Meeting.
May 13, 2024
·
5 min read
Drug Development
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
IN8bio, Inc. a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced the presentation of new preclinical data for its non-signaling gamma-delta T cell based Chimeric Antigen Receptor T cell platform, INB-300.
March 5, 2024
·
5 min read
Press Releases
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
August 12, 2024
·
9 min read
Pharm Country
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2)
May 6, 2024
·
1 min read
Pharm Country
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
LAVATherapeutics N.V. (Nasdaq:LVTX), a company in the clinical stage of immuno-oncology, is dedicated to advancing its unique Gammabody™ platform, which involves the development of bispecific gamma-delta T cell engagers.
June 1, 2023
·
5 min read
Pharm Country
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
IN8bio, Inc., a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is proud to announce its upcoming Research & Development Day on Thursday, October 12, 2023.
September 26, 2023
·
3 min read
Pharm Country
IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
IN8bio, Inc. today announced positive preclinical data underscoring the potential of its DeltEx Gamma-Delta T cells to target and kill ovarian cancer.
May 17, 2023
·
6 min read
Pharm Country
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
IN8bio, Inc. today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer.
February 14, 2024
·
8 min read
Drug Development
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the completion of enrollment in the Phase 1 study of INB-100 in leukemia patients and the initiation of patient enrollment in the Phase 2 clinical trial evaluating INB-400 in newly diagnosed glioblastoma multiforme (GBM).
October 12, 2023
·
7 min read
1 of 26,047
Next